WO1998014208A9 - Reactive ligands and covalent ligand-protein complexes - Google Patents
Reactive ligands and covalent ligand-protein complexesInfo
- Publication number
- WO1998014208A9 WO1998014208A9 PCT/US1997/017483 US9717483W WO9814208A9 WO 1998014208 A9 WO1998014208 A9 WO 1998014208A9 US 9717483 W US9717483 W US 9717483W WO 9814208 A9 WO9814208 A9 WO 9814208A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- amino
- bonded
- amino acid
- peptide
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 150
- 239000003446 ligand Substances 0.000 title claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 150000001875 compounds Chemical class 0.000 claims description 69
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 55
- 125000000539 amino acid group Chemical group 0.000 claims description 50
- 239000004475 Arginine Substances 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000003277 amino group Chemical group 0.000 claims description 30
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 29
- -1 amino, substituted amino, hydroxyl Chemical group 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 230000000890 antigenic Effects 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000005210 alkyl ammonium group Chemical group 0.000 claims description 11
- 230000000269 nucleophilic Effects 0.000 claims description 11
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 10
- 125000004069 aziridinyl group Chemical group 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 9
- 125000005228 aryl sulfonate group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 150000002118 epoxides Chemical class 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 150000007942 carboxylates Chemical class 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 125000005227 alkyl sulfonate group Chemical group 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 9
- 230000001413 cellular Effects 0.000 abstract description 6
- 210000000987 Immune System Anatomy 0.000 abstract description 5
- 230000002441 reversible Effects 0.000 abstract description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 39
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 36
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 35
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- 235000009697 arginine Nutrition 0.000 description 25
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 18
- 150000003573 thiols Chemical class 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 108010016626 Dipeptides Proteins 0.000 description 13
- 210000001744 T-Lymphocytes Anatomy 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 241000272168 Laridae Species 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- 210000004027 cells Anatomy 0.000 description 8
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 108091008153 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 235000008521 threonine Nutrition 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 4
- 229960002989 Glutamic Acid Drugs 0.000 description 4
- 102000026088 HLA-A2 Antigen Human genes 0.000 description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 4
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 4
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 229960003180 Glutathione Drugs 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- IMTFCMAYCACCFT-FQBJPRASSA-N (2S)-6-amino-2-[[2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-(diaminomethylideneamino)butanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]am Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCN=C(N)N)NC(=O)CN)CC1=CC=CC=C1 IMTFCMAYCACCFT-FQBJPRASSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- MGEVGECQZUIPSV-UHFFFAOYSA-N BOP reagent Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 MGEVGECQZUIPSV-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 150000001541 aziridines Chemical group 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 150000003738 xylenes Chemical class 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N Aminocaproic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229960000789 Guanidine Hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 102100020459 HLA-B Human genes 0.000 description 1
- 101710009008 HLA-B Proteins 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N Iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N Methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- FVSXTKSUFAVKLA-UHFFFAOYSA-N NC(C(=O)O)CCCC=C.C(=O)(OC(C)(C)C)NCC(=O)O Chemical compound NC(C(=O)O)CCCC=C.C(=O)(OC(C)(C)C)NCC(=O)O FVSXTKSUFAVKLA-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical group C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 230000013564 activation of immune response Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000139 costimulatory Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 101700022040 his-42 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- ZEABYRLMGDTEAI-UHFFFAOYSA-M lithium;methanol;hydroxide Chemical compound [Li+].[OH-].OC ZEABYRLMGDTEAI-UHFFFAOYSA-M 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Definitions
- Ligand protein interactions influence many factors of biological systems. Ligands bind to proteins according to particular kinetic profiles. For example, antigenic peptides of T cells first bind to class I or class II major histocompatibility complex (MHC) molecules before interacting with T cell receptors on CD 8+ T cells or CD + T cells to elicit immune responses. Stern, L.J. & Wiley, D.C. (1994), Structure 2, 245-251. In general , conservative residue substitutions in the middle portion of antigenic peptides of T cells are introduced to selectively inhibit activation of T cells without significantly altering binding affinity to the relevant MHC molecules. See, Sloan-Lancaster, J., Evavold, B.D. & Allen, P.M.
- MHC-blocking peptides have included the replacement of several residues from the middle portion of antigenic peptides with moieties such as 4-aminobutyric acid, 6-aminohexanoic acid, and phenanthridine to act as spacers.
- moieties such as 4-aminobutyric acid, 6-aminohexanoic acid, and phenanthridine to act as spacers.
- the reversible kinetics of binding lead to the release of the ligand from the binding site, thereby influencing recognition of the ligand-protein complex.
- By changing the kinetics of binding it is possible to alter the response to the cellular immune system.
- covalent complexes of peptides with MHC molecules have been constructed previously by generating recombinant proteins with elongated N-termini that extended into the binding grooves of MHC class I (see, e.g., Mottez, E., Langlade-Demoyen, P., Gournier, H., Martinon, F., Maryanski, J. , Kourilsky, P. & Abastado, J.-P.
- the present invention features compounds that bind as ligands to a binding region of a protein.
- the compounds react with residues in the binding region, selectively forming a covalent bond between the protein and the ligand.
- the formation of the covalent bond changes the reversibility of the binding kinetics between the ligand and the protein.
- the invention relates to a compound of the formula (I)
- An alkyl group is a branched or unbranched C x to C 6 alkyl or benzyl
- aryl is a substituted or unsubstituted C 6 to C 14 carbocyclic or heterocyclic aromatic having one or two rings.
- a substituted aryl is an aryl bearing one or more ⁇ to C 6 substituents including alkyl, alkoxy, or acyl groups, or halogen, hydroxy, amino, or amido groups.
- a substituted amino is an amino group having one or two branched or unbranched C ⁇ to C 6 alkyl or benzyl groups.
- R x is halogen, alkyl sulfonate, carboxylate, or aryl sulfonate and R 2 is hydroxy, amino, alkylamino, ammonium, or alkyl ammonium, or together R x and R 2 are O, NH 2 ⁇ or NH;
- X is a C 2 to C 4 alkyl;
- R 3 is H;
- R 4 is -NH-W, where W is an amino acid residue bonded at its carbonyl group or a peptide moiety bonded at its terminal carbonyl group; and
- W is an amino acid residue bonded at its carbonyl group and Y' is a peptide moiety bonded at its terminal amino group.
- R x is alkyl sulfonate and R 2 is an ammonium, or together R : and R 2 are 0, or NH; X is C Pain alkyl; and the amino acid residue is a glycine residue.
- a portion of the peptide moiety is identical to a portion of a selected peptide or an antigenic peptide.
- the peptide moiety can preferably contain between 2 and 10 amino acid residues.
- the compound is G(az)IDKPILK or G (az) AFVTIGK, where (az) is an unnatural amino acid residue where the side chain is a C 6 alkyl having a terminal aziridine group .
- a further aspect of this invention relates to a method of forming a ligand-protein complex.
- the method includes the steps of providing a protein having an arginine-specific binding region, the binding region including a nucleophilic residue, and adding a ligand to bind with the protein at the arginine-specific binding region, the ligand having a moiety which reacts with the nucleophilic residue.
- the moiety of the ligand and the nucleophilic residue of the protein form a covalent bond between the ligand and the protein.
- the arginine-specific binding region includes a thiol , a thiol and a carboxyl , or two carboxyl groups, and the moiety is halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, carboxylate, a Michael acceptor, aziridine, or epoxide.
- the arginine-specific binding region includes a thiol and a carboxyl and the moiety is aziridine, or epoxide.
- the step of providing the protein includes the step of altering a binding region of the protein to introduce the arginine-specific binding region.
- Another aspect of this invention relates to a covalently linked ligand-protein complex including a protein having an arginine-specific binding region and a ligand covalently bonded to the binding region of the protein, said ligand having the formula
- R ⁇ and R 2 is hydroxy, alkyl, alkyl carbonyl, amino, alkyl amino, ammonium, or alkyl ammonium, and the other of R x and R 2 is the covalent bond to the protein;
- X is C x to C 6 alkyl, substituted aryl, or deleted;
- R 3 is H, alkyl, or aryl;
- Y is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group; and
- the arginine-specific binding region includes a thiol, a thiol and carboxyl, or two carboxyl groups;
- R x is the covalent bond between the ligand and the protein;
- R 2 is hydroxy, alkyl, alkyl carbonyl, amino, alkyl amino, ammonium, or alkyl ammonium;
- R 3 is H;
- X is a C 2 to C 4 alkyl.
- R 2 is the covalent bond between the ligand and the protein (i.e., a thioether or ester linkange) .
- the invention includes one or more of the following advantages.
- the ligand selectively reacts with groups in the binding region of the protein. Thus, undesired reactions outside of the binding region are unlikely to occur.
- the covalent nature of the linkage between the ligand and the protein changes the kinetics of ligand binding dramatically by making the ligand binding essentially irreversible.
- a "selected peptide” is any peptide or variant thereof that is associated with an undesired physical condition, such as, but not limited to, an immune system- selective peptide (i.e., a peptide that induces an immune response) .
- an antigenic peptide mentioned herein can be either a naturally occurring peptide or a variant thereof (e.g., containing an acetylated alpha- amino group, an amidated alpha-carboxyl group, a D- and/or beta- or gamma-amino acid residue, or any suitable organic moiety) ; indeed, there are only two criteria, i.e., it is a peptide and it binds to a class I or class II MHC molecule in the manner described in Stern, L.J. & Don C. Wiley, Structure (1994) 2, 245-251.
- FIG. 1 is a schematic diagram depicting the synthesis and structure of a compound according to the invention.
- Fig. 2 is a drawing of a model of the P2 pocket of HLA-B27 binding arginine (Fig. 2A) , a model of an aziridine-containing ligand (Fig. 2B) and a covalently bonded residue (Fig. 2C) .
- Fig. 3 is a graph of three HPLC runs depicting the stability of the aziridine ligand to free thiols in solution.
- Fig. 4 is an image of an SDS-PAGE (15%) of HLA-B27 complexed with the aziridine-containing peptide (G(az) IDKPILK) (lane 1) and the control peptide (GRIDKPILK) (lane 2) .
- Ligands bind to proteins according to particular kinetic profiles. Short peptides containing arginine at peptide position 2 (P2) bind to arginine-specific binding regions of class I major histocompatibility complex (MHC) glycoproteins, such as HLA-B27.
- MHC major histocompatibility complex
- HLA-B27/peptide complex is recognized by particular T cells. This recognition leads to both the development of the repertoire of T cells in the cellular immune system and the activation of cytotoxic T cells.
- the reversible kinetics of binding lead to release of the ligand from the binding site, thereby affecting the recognition of the ligand-protein complex. By changing the kinetics of the reversible binding, it is possible to alter the response to the cellular immune system.
- Reactive ligands can be used to change the kinetics of binding by reacting with the protein when bound.
- Suitable reactive ligands for changing the kinetics of binding with protein substrates are compounds of the formula I.
- Each of R x and R 2 is hydroxy, halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, carboxylate, a Michael acceptor, amino, alkylamino, ammonium, or alkyl ammonium.
- R ⁇ and R 2 are O, NH, NH 2 + , or NZ, where Z is alkyl, or aryl, thus forming an epoxide, aziridine or substituted aziridine ring.
- X a spacer group, is C x to C 6 alkyl, substituted aryl, or deleted.
- R 3 is H, alkyl, or aryl.
- one of R x and R 2 is a reactive group that will react with a nucleophile (e.g., -SH, -NH 2 , -OH, or -COO") .
- a nucleophile e.g., -SH, -NH 2 , -OH, or -COO
- one of the groups is a leaving group or contains a leaving group.
- the leaving group can be a halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, alkyl carboxylate, ammonium, alkyl ammonium, epoxide, aziridine, or substituted aziridine, where the alkyl group is a branched or unbranched C x to C 6 alkyl or benzyl and aryl is a substituted or unsubstituted C 5 to C 14 carbocyclic or heterocyclic aromatic having one or two rings.
- the reactions between the group at R x or R 2 and the nucleophile take place at a binding region of a protein.
- the compounds of the invention can be used to prepare reactive ligands, or are themselves reactive ligands that can be used to make covalent ligand-protein complexes in vi tro or in vivo .
- R 4 and R 5 is a reactive group or the peptide moiety or amino acid residue is ultimately a group that binds selectively to a protein.
- a portion of the peptide moiety, the amino acid residue, or a combination thereof is a selected peptide or an antigenic peptide, which can be either a naturally occurring peptide or a variant thereof (e.g., containing an acetylated alpha-amino group, an amidated a-carboxyl group, a D- and/or beta- or gamma- amino acid residue, or any suitable organic moiety) .
- a portion of the peptide moiety, the amino acid residue, or their combination is a peptide and it binds to a class I or class II MHC molecule in the manner described in Stern, L.J.
- short peptides containing arginine at peptide position 2 bind to arginine-specific binding regions of class I major histocompatibility complex (MHC) glycoproteins, such as HLA-B27.
- MHC major histocompatibility complex
- HLA-B27/peptide complex is recognized by particular T cells.
- Fig. 1 is a schematic diagram depicting the synthesis and structure of a compound according to the invention.
- Abbreviations are Boc, butoxycarbonyl ; Ph, phenyl; DEAD, diethyl azodicarboxylate; THF, tetrahydrofuran; DMS, dimethyl sulfide; TFA, trifluoroacetic acid; Gly, glycine; BOP, benzotriazol-1- yloxy-tris (dimethylamino)phosphonium hexafluorophosphate; HOBT, 1-hydroxybenzotriazole; DIEA, diisopropyl ethylamine; MCPBA, m-chloroperoxybenzoic acid; EtOAc, ethyl acetate; Ms, mesyl ; Me, methyl; HBTU 2-(lH- benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluoro
- the first two steps shown in Fig. 1 can be modified to prepare variants of Compound 1, where the length of the alkenyl group can be varied, or other functionalities can be added using ordinary synthetic methods.
- Boc-amine (Compound 1) was prepared according to the methods described in Arnold, L.D., Kalantar, T.H. & Vederas, J.C. (1985) J. Am. Chem. Soc. 107, 7105-7109, and Arnold, L.D., Drover, J.C. G. & Vederas, J.C. (1987) J. Am. Chem. Soc. 109, 4649-4659 and the dipeptides were prepared according to the methods described in Arnold, L.D., Kalantar, T.H.
- the olefinic group of Compound 1 can be transformed by ordinary methods, e.g., addition reactions.
- the subsequent reactions of Compound 1 and its analogues can be carried out to link other natural or unnatural amino acid residues or peptide moieties.
- a ligand-protein complex is formed by exposing a protein having an arginine-specific binding region which includes a nucleophilic residue to a ligand which binds with the protein at the arginine-specific binding region.
- the ligand is a compound of the invention, thus having a moiety which reacts with the nucleophilic residue.
- the reactive moiety of the ligand and the nucleophilic residue of the protein form a covalent bond between the ligand and the protein, resulting in a covalently linked ligand-protein complex where the protein and ligand become linked at R x or R 2 , changing the kinetics of release of the ligand from the binding site.
- Cytotoxic T-lymphocytes recognize antigens as short peptides bound to MHC class I molecules that consist of a heavy chain (H) and 3 2 -microglobulin ( ⁇ 2 -m) .
- H heavy chain
- ⁇ 2 -m 3 2 -microglobulin
- HLA-B27 has been implicated in, for example, the autoimmune disorder ankylosing spondylitis. See, Brewerton, D.A., Caffrey, M., Hart, F.D., James, D.C.O., Nicholls, A. & Sturrock, R.D. (1973) Lancet 1, 904-907, Schlosstein, L. , Terasaki, P.I., Bluestone, R. & Pearson, CM. (1973) N. Engl . J. Med. 288, 704-706, and Hammer, R.E., Maika, S.D., Richardson, J.A., Tang, J.-P. & Taurog, J.D.
- the autoimmune response involves binding of an autoantigen peptide by HLA-B27.
- Endogenous and viral peptides that bind to HLA-B27 have an arginine in their P2 position, as described by Jardetzky, T.S., Lane, W.S., Robinson, R.A. , Madden, D.R. & Wiley, D.C. (1991) Nature 353, 326-329.
- the d-guanidinium group of the arginine is bound within a deep pocket where four polymorphic residues project toward it. See, Madden, D.R., Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1991) Nature 353, 321-325, and Madden, D.R. , Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1992) Cell 70, 1035-1048.
- T cell receptors on CD8 + and CD4 + T cells requires the recognition of antigenic peptides bound in the groove of MHC molecules on the surface of antigen-presenting cells.
- Antigenic peptides bind in an extended conformation to class I and class II MHC molecules.
- X-ray crystallography studies have revealed that for all class I MHC complexes, the peptide N- and C- termini form hydrogen bonds with conserved MHC amino acid residues located at both ends of the binding site, some peptide side chains are buried in deep pockets along the binding site, and the central region of the peptide arch away from the floor of the binding site with side chains generally pointing toward T cell receptors.
- Antigenic peptides of 8- to 10-amino acids long have been shown to adopt this mode of binding.
- a decamer has been shown to extend out of the binding groove at the C-terminus and an octamer has been shown to preferentially leave the N- terminal end of the binding site unoccupied.
- other modes of binding can be described: extension of a decamer out of the N- terminal end of the binding site and binding of an octamer preferentially at the N-terminal end of the groove leaving the C-terminal end of the groove unoccupied.
- class II MHC molecules bind to longer antigenic peptides.
- This difference in length can be ascribed to structural differences between the two binding sites and the position of key MHC amino acid residues that interact with the peptide backbone.
- the few X-ray structures of class II MHC complexes that have been determined so far indicate that the antigenic peptide is stretched out along most of its length and adopts a bound conformation characteristic of a type II polyproline helix.
- the peptide' s N- and C-termini extend out of the binding groove.
- Side chains of some amino acid residues bind specifically in pockets made of polymorphic MHC amino acid residues while other side chains, spaced approximately three amino acid residues apart, point away from the binding site.
- Interaction of T cell receptors with both types of MHC complexes involves amino acid residues on both the peptide and MHC molecules.
- amino acid residues from the central portion of the peptide, where side chains are most exposed play a more crucial role in this recognition event
- amino acid residues having side chains pointing up are found along the entire sequence.
- references for the structures of class I MHC molecules include: Madden, D.R., Garboczi, D.N. & Wiley, D.C. (1993) Cell 75, 693-708; Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., Strominger, J.L. & Wiley, D.C. (1987) Nature 329, 506-512; Madden, D.R., Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1991) Nature 353, 321-325; Silver, M.J., Guo, H.-C, Strominger, J.L. & Wiley, D.C. (1992) Nature 360, 367-369; Guo, H.-C, Jadertzky, T.S., Garrett, T.P.J., Lane, W.S., Strominger,
- a ligand was synthesized with a reactive side chain designed to mimic arginine. Although other reactive groups at this position can be used, an aziridine is most preferred.
- the reactive ligand contains an aziridine and binds covalently by reaction of the aziridine upon binding in the arginine-specific P2 pocket of HLA-B27.
- a peptide was designed such that a covalent bond with HLA-B27 will form between the ligand and the protein spontaneously and selectively upon binding.
- An aziridine-containing amino acid mimic of arginine was selected (Fig. 2B) . According to Fig. 2B) . According to Fig.
- the aziridine-containing ligand can bind in place of the guanidinium group with the aziridine amine, forming a hydrogen bonded salt bridge to Glu-45.
- the free thiol of Cys-67 is poised for in-line nucleophilic attack of the aziridine group.
- Fig. 2C shows the expected geometry of the covalent complex between Cys-45 and the aziridine- containing peptide that results from the nucleophilic attack of the thiol which opens the aziridine group.
- the positively charged secondary amine of the aziridine ring is expected to form a hydrogen-bonded charged-pair with Glu-45 in the arginine-specific pocket, positioning the eta-carbon of the aziridine ring for an in-line, ring- opening attack by the thiolate of Cys-67 (Fig. 2C) .
- Selectivity is expected from the polarizability of the aziridine by Glu-45 and the propinquity of the Cys-67 thiol to the bound aziridine ring.
- the aziridine- containing ligand is shown to alkylate specifically cysteine 67 of HLA-B27.
- free cysteine in solution nor an exposed cysteine on a class II MHC molecule can be alkylated, showing that specific recognition between the anchor side-chain pocket of an MHC class I protein and the designed ligand (propinquity) is necessary to induce the selective covalent reaction with the MHC class I molecule.
- the aziridine within the ligand was cyclized from the mesylate in solution, before addition to the folding buffer containing recombinantly expressed, purified HLA- B27 heavy chain and ⁇ 2 -m.
- Activation and regulation of immune responses can be influenced by the compounds of the invention, since the compounds bind to specific protein binding pockets irreversibly. It is possible to activate T cell responses by treatment with a preformed ligand-protein complex or by treatment with the reactive ligand or a precursor thereof.
- Nonamer peptides containing the aziridine were synthesized by coupling the dipeptide to synthetic heptamers corresponding to the seven C-terminal amino acids of two peptides known to bind to HLA-B27, GRIDKPILK and GRAFVTIGK. See, Jardetzky, T.S., Lane, W.S., Robinson, R.A. , Madden, D.R. & Wiley, D.C. (1991) Nature 353, 326-329.
- the peptide sequence of the ligand shown in Fig. 1 and described here is based upon a ribosomal peptide GRIDKPILK. Other peptide sequences and analogues can be substituted in the scheme shown in Fig.
- Boc-amine (Compound 1) .
- Boc-amine Compound 1 was prepared according to the methods described in Arnold, L.D., Kalantar, T.H. & Vederas, J.C (1985) J. Am. Chem. Soc. 107, 7105-7109, and Arnold, L.D., Drover, J.C.G. & Vederas, J.C. (1987) J. Am. Chem. Soc. 109, 4649-4659.
- Boc-Glycine- (2-amino-hept-6-enoic acid) dipeptide methyl ester (Compound 2) .
- Compound 1 211 mg, 0.911 mmol
- CH 2 C1 2 5.0 mL
- trifluoroacetic acid 5.0 mL
- the mixture was swirled, allowed to stand for 20 minutes, diluted with 4 mL of toluene, and concentrated in vacuo to afford the crude deprotected amine.
- the deprotected amine was dissolved in 5.0 mL of CH 2 C1 2 .
- Diisopropyl ethylamine (0.476 mL, 0.273 mmol) was added to the solution containing the deprotected amine, followed by Boc-glycine (175 mg, 1.00 mmol) and benzotriazol-1-yloxy- tris (dimethylamino)phosphonium hexafluorophosphate (442 mg, 1.00 mmol) .
- Boc-glycine (175 mg, 1.00 mmol
- benzotriazol-1-yloxy- tris (dimethylamino)phosphonium hexafluorophosphate (442 mg, 1.00 mmol)
- the mixture was stirred for 6 hours and then quenched by adding 5 drops isopropyl amine.
- the mixture was concentrated in vacuo and chromatographed (40% ethyl acetate :hexanes) to give 178 mg (0.542 mmol, 59%) of Compound 2.
- Compound 3 was characterized by: IR (Film) : n 2934, 1744, 1719, 1678, 1524, 1456, 1437, 1412, 1391, 1368, 1250, 1211, 1171, 1051, 1030, 939, 864, 835, 781, 615 cm “1 ; *H NMR (CDC1 3 ) : d 1.41 (s) , 1.48 (m) , 1.52 (m) , 1.62 (m) , 1.82 (m) , 2.40 (q) , 2.69 (t) , 2.84 (t), 3.69 (s) , 3.78 (m) , 4.57 (q) , 5.26 (d) , 6.71; and 13 C NMR (CDC1 3 ) : d 24.82, 25.32, 25.38, 28.16, 31.94, 44.10, 46.77, 51.87, 51.96, 52.20, 79.92, 156.02, 169.41, 172.59
- Azido Dipeptide (Compound 4) .
- NH 4 C1 80 mg, 1.49 mmol
- NaN 3 300 mg, 4.61 mmol
- the mixture was heated to reflux and stirred for 2 hours.
- the mixture was then cooled to 25°C, diluted with 40 mL of ethyl acetate, washed with water (2 x 20 mL) , washed with brine (10 mL) dried over MgS0 4 , and concentrated in vacuo to give 71.0 mg (0.191 mmol, 100%) of azido dipeptide Compound 4.
- Compound 4 was characterized by: IR (Film) : n 3328, 2976, 2936, 2865, 2101, 1742, 1671, 1524, 1439, 1393, 1368, 1279, 1252, 1217, 1167, 1051, 1030, 941, 864, 632 cm “1 ; L H NMR (CDCl 3 ) : d 1.28 (m) , 1.38 (s) , 1.61 (m) , 1.79 (m) , 1.82 (d) , 3.17 (m) , 3.24 (m) , 3.66 (s) , 3.74 (m) , 4.52 (m) , 5.49 (t) , 6.90 (d) ; and 13 C NMR (CDC1 3 ) : d 24.60, 24.72, 24.82, 28.19, 32.01, 33.80, 44.09, 51.75, 51.89, 52.34, 56.86, 64.84, 70.12, 70.38, 80.
- Boc-amine Dipeptide (Compound 5) .
- a 5% solution of Pd on carbon in ethyl acetate (6.0 mL) was stirred at room temperature, under atmospheric pressure of hydrogen gas, for one hour.
- Addition of Compound 4 (82.3 mg, 0.24 mmol) and Boc-anhydride (104.3 mg, 0.48 mmol) required 1.0 mL ethyl acetate, followed by two ethyl acetate washes of 1.0 mL each. After stirring 12 hours, and Celite was added. The solution was filtered and concentrated in vacuo . The residue was purified by flash chromatography, running neat ethyl acetate, to yield 86.6 mg (0.188 mmol, 78%) of Boc-amine dipeptide Compound 5.
- Compound 5 was characterized by: IR (Film) : n 3328, 2978, 2934, 2865, 1744, 1686, 1524, 1456, 1439, 1412, 1393, 1368, 1275, 1250, 1169, 1051, 1030, 864, 781, 735 cm “1 ; ⁇ NMR (CDC1 3 ) : d 1.39 (s) , 1.41 (s) , 1.48 (t) , 1.64 (m) , 1.81 (m) , 2.92 (m) , 3.22 (br s) , 3.60 (d) , 3.69 (s) , 3.77 (d) , 4.55 (m) , 5.13 (br s) , 5.43 (d) , 6.86 (br s) ; and 13 C NMR (CDC1 3 ) : d 24.56, 24.73, 24.95, 28.08, 31.71, 33.90, 43.82, 46.35, 51.75
- the polypeptide was cleaved from the resin using 95% trifluoroacetic acid in water to afford the mesylate polypeptide Compound 8.
- Compound 8 was purified by reverse phase HPLC, running a gradient from 85:15 to 50:50 (water with 0.1% 0 trifluoroacetic acid:methanol) . Mass spectrometry confirmed the identity of Compound 8 (MH + 1133) .
- Aziridine Polypeptide (Compound 9) .
- Compound 8 was treated with sodium hydroxide (10 equivalents at room temperature for half an hour) , or lithium hydroxide in methanol, to afford aziridine polypeptide Compound 9.
- Mass spectrometry confirmed the identity of Compound 9 (MH + 1055) .
- Compound 9 was subjected to Edman degradation and microsequencing, which confirmed its composition to be G (az) IDKPILK, where (az) is the unnatural aziridine amino acid residue.
- the polypeptide G(az)AFVTIGK was prepared using a different resin-bound peptide.
- the aziridine within a peptide was cyclized from the mesylate in solution before addition to the folding buffer containing recombinantly expressed, purified HLA-B27 heavy chain and jS 2 -m.
- the solution contained approximately equimolar distributions of mesylate precursor Compound 8 and aziridine-containing ligand Compound 9 (verified by reverse phase HPLC) and the solution was added to the folding buffer (both Compound 8 and Compound 9 have a final concentration of 0.1 mM in the folding buffer), which was incubated at 10°C After half an hour and approximately every 12 hours later, 100 mL of the folding buffer was removed and subjected to reverse phase HPLC, running a gradient of 100:0 to 40:60 (0.1% trifluoroacetic acid in water : acetonitrile) over 30 minutes and monitoring at 214 nm.
- HLA-DR1 containing the only free cysteine, Cys-30, does not bind arginine and lacks the glutamate and threonine of the arginine binding pocket in HLA-B27 (see, Stern, L.J., Brown, J.H. , Jardetzky, T.S., Gorga, J.C, Urban, R.G. , Strominger, J.L. & Wiley, D.C.
- the aziridine ligand alkylates Cys-67 during the folding of recombinant HLA-B27 despite a 5000 molar equivalent excess of cysteine in the glutathione of the refolding buffer.
- the ligand was described in Garboczi, D.
- the lower yields might result from less efficient hydrogen bonding to the aziridine moiety compared to the planar guanidinium group of the control peptide, or decreased reactivity of one diastereomer of the aziridine ligand Compound 9 (kinetic resolution) .
- the folding of HLA-B27 was dependent upon a peptide ligand, in this case containing aziridine (Compound 9) .
- HLA-A2 an MHC molecule lacking specificity for arginine at P2 , failed to fold in the presence of the aziridine-containing peptide, as expected.
- Characterization of Covalent Ligand-Protein Bond The aziridine-containing ligands were shown to form covalent bonds with HLA-B27 by a shift in mobility of the heavy chain on SDS-PAGE; reaction with Cys-67 was shown by tryptic digestion, mass spectrometry (MS) , and Edman microsequencing.
- Fig. 4. depicts the results of an SDS-PAGE (15 %) of HLA-B27 complexed with the aziridine-containing peptide (G(az) IDKPILK (lane 1) and the control peptide (GRIDKPILK) (lane 2) .
- the SDS-PAGE of HLA-B27 complexed with aziridine-peptides revealed a mobility shift of the heavy chains of the complex due to addition of the aziridine-containing ligand (Fig.4, lane 1), when compared to heavy chain from complexes with the same peptides with arginine in the P2 position (Fig. 4, lane 2) .
- the mobility of /3 2 -m remained unchanged.
- the aziridine-modified complex was digested with trypsin and the fragments separated by reverse phase HPLC.
- the carboxyamidomethylated tryptic peptides were separated by narrow-bore HPLC using a Vydac C18 2.1 x 150 mm reverse phase column on a Hewlett-Packard 1090 HPLC/1040 diode array detector. Putative difference peaks from the chromatogram were chosen based on differential UV absorbance at 210, 277, and 292 nm.
- Microcapillary HPLC/electrospray ionization/tandem mass spectrometry on a Finnigan TSQ7000 triple quadrupole mass spectrometer (San Jose, CA) as described in Hunt, D. F., Henderson, R.A. , Shabanowitz, J., Sakaguchi, K. , Michel, H., Sevilir, N. , Cox, A.L., Appella, E. & Engelhard, V.H. (1992) Science 255, 1261- 1263.
- the chromatogram of the proteolyzed fragments was compared with a tryptic digest of the MHC class I protein formed with the arginine-containing parent-peptide
- GIDKPILK Matrix-assisted laser desorption time-of- flight MS was used to screen rapidly putative difference peaks, which were deficient in UV absorbance at 277 and 292 nm (lacking tyrosine and tryptophan) .
- Edman microsequencing revealed this fraction to contain the peptide ligand in equimolar amounts with the HLA-B27 heavy chain fragment containing Cys-67.
- thermodynamic stability of Covalent MHC-peptide Complexes The thermodynamic stability of the class I MHC molecules from mouse and human have been shown to depend on the sequence of the bound peptide. See, Bouvier, M. & Wiley, D.C. (1994) Science 265, 398-402, Fahnestock, M.L., Tamir, I., Narhi, L.O. & Bjorkman, P.J. (1992) Science 258, 1658- 1662, and Fahnestock, M.L., Johnson, J.L., Renny Feldman, R.M. , Tsomides, T.J., Mayer, J. , Narhi, L.O. & Bjorkman, P.J. (1994) Biochemistry 33, 8149-8158.
- the thermal transition of the HLA-B27 complexes was measured using circular dichroism (CD) .
- thermoelectric temperature controller was used to obtain thermal denaturation curves in triplicate, from 25-95 'C, as described in Bouvier, M. & Wiley, D.C. (1994) Science 265, 398-402.
- the addition of 50 mM NaCl to the typical 10 mM MOPS (pH 8.0) buffer was found to prevent aggregation of HLA-B27.
- the additional salt had no effect on the measured melting temperature (T m ) of the HLA-A2 complex formed with a hepatitis B-derived peptide.
- the covalent complexes of HLA-B27 with two aziridine-containing-peptides, G(az) IDKPILK (Compound 9) and G (az) AFVTIGK, both denature at approximately the same temperature, 62 °C G(az) AFVTIGK was prepared by coupling a different peptide to Compound 8
- the non-covalent complexes of HLA-B27 with the cognate peptides (GRIDKPILK and GRAFVTIGK) melted at 72°C and 60°C, respectively.
- the data indicate that covalently bound peptides with an aziridine replacing arginine stabilize HLA molecules approximately like non-covalently bound peptides, in one case stabilizing slightly more and in one less.
- Covalent MHC-peptide complexes like those reported here may find use generating anergy if administered alone (see, Kozono, H. , White, J., Clements, J. , Marrack, P. & Kappler, J. (1994) Nature 369, 151-154) or activation if administered with co-ligands for inducing costimulatory signals as suggested by Schwartz, R.H. (1992) Cell 71, 1065-1068.
- a non-peptide ligand capable of crossing cellular membranes to block selectively HLA-B27, based on the same aziridine specificity can also be prepared.
- the strategy can be used to form covalent complexes of peptides or other ligands with HLA- B27 does not add any new amino acids to the surface of the MHC molecule (that might be immunogenic) , but instead forms the covalent attachment deep in a pocket buried by the bound peptide.
- the aziridine strategy can be generalized to other proteins (i.e., recombinant class I MHC molecules) by mutating residues in the binding region (i.e., the P2 pocket residues) to those in HLA-B27.
- the reverse experiment, engineering an HLA-A2 P2 specificity pocket into HLA-B27 by mutating residues 9, 24, 45, 66, 67, and 70 has been reported by Colbert, R.
- peptide analogs obtained by back modification of the above-described MHC-blocking peptides, e.g., replacement of at least one of the peptide bonds with -CH 2 -NH-, CH 2 -S-, or the like.
- alkyl groups can be readily substituted by alkenyl, alkynyl or alkyl ether groups.
Abstract
Ligands bind to proteins according to particular kinetic profiles. The reversible kinetics of binding lead to release of the ligand from the binding site, thereby affecting the recognition of the ligand-protein complex. By changing the kinetics of the reversible binding, it is possible to alter the response to the cellular immune system. Reactive ligands can be used to change the kinetics of binding by reacting with the protein when bound.
Description
REACTIVE LIGANDS AND COVALENT LIGAND-PROTEIN COMPLEXES
BACKGROUND OF THE INVENTION Ligand protein interactions influence many factors of biological systems. Ligands bind to proteins according to particular kinetic profiles. For example, antigenic peptides of T cells first bind to class I or class II major histocompatibility complex (MHC) molecules before interacting with T cell receptors on CD8+ T cells or CD+ T cells to elicit immune responses. Stern, L.J. & Wiley, D.C. (1994), Structure 2, 245-251. In general , conservative residue substitutions in the middle portion of antigenic peptides of T cells are introduced to selectively inhibit activation of T cells without significantly altering binding affinity to the relevant MHC molecules. See, Sloan-Lancaster, J., Evavold, B.D. & Allen, P.M. (1993) Nature 363, 156-159; De Magistris, M.T., Alexander, J. , Coggeshall, M., Altman, A., Gaeta, F.C.A., Grey, M.H. & Sette, A. (1992) Cell 68, 625-634; and Alexander, J., Snoke, K. , Ruppert, J., Sidney, J., Wall, M., Southwood, S., Oseroff, C, Arrhenius, T., Gaeta, F.C.A., Colon, S.M., Grey, H.M. & Sette, A. (1993) J. Immunol. 150, 1-7. Other designs of MHC-blocking peptides have included the replacement of several residues from the middle portion of antigenic peptides with moieties such as 4-aminobutyric acid, 6-aminohexanoic acid, and phenanthridine to act as spacers. E.g., see Rognan, D., Scapozza, L., Folkers, G. & Daser, A. (1995) Proc . Natl . Acad. Sci. USA 92, 753-757.
The reversible kinetics of binding lead to the release of the ligand from the binding site, thereby influencing recognition of the ligand-protein complex. By changing the kinetics of binding it is possible to alter the response to the cellular immune system. For example, covalent complexes of peptides with MHC
molecules have been constructed previously by generating recombinant proteins with elongated N-termini that extended into the binding grooves of MHC class I (see, e.g., Mottez, E., Langlade-Demoyen, P., Gournier, H., Martinon, F., Maryanski, J. , Kourilsky, P. & Abastado, J.-P. (1995) Journal of Experimental Medicine 181, 493- 502) and MHC class II (see, e.g., Kozono, H. , White, J. , Clements, J., Marrack, P. & Kappler, J. (1994) Nature 369, 151-154) molecules. These molecules are active and have been suggested as possible therapeutics to induce T- cell tolerance in cases where the peptide autoantigens can be identified. See, for example, Kozono, H., White, J., Clements, J., Marrack, P. & Kappler, J. (1994) Nature 369, 151-154 and Sharma, S. D., Nag, B., Su, X.-M., Green, D., Spack, E., Clark, B.R. & Sriram, S. (1991) Proc. Natl. Acad. Sci. USA 88, 11465-11469.
SUMMARY OF THE INVENTION The present invention features compounds that bind as ligands to a binding region of a protein. The compounds react with residues in the binding region, selectively forming a covalent bond between the protein and the ligand. The formation of the covalent bond changes the reversibility of the binding kinetics between the ligand and the protein. In one aspect, the invention relates to a compound of the formula (I)
where each of Rx and R2, independently, is hydroxy, halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, alkyl carboxylate, a Michael acceptor, amino, alkylamino, ammonium, or alkyl ammonium, or together Rx and R2 are 0, NH, NH2 +, or NZ, where Z is alkyl or aryl; X is Cx to C6 alkyl, substituted aryl, or deleted; R3 is H, alkyl, or aryl; R4 is alkyl, aryl, -NH- W, or -C(=0)-Y, where W is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y is alkyl, alkoxy, amino, substituted amino, hydroxyl , a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group; and R5 is H, alkyl, aryl, -NH-W' , or -C(=0)-Y', where W' is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y' is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group, or an amino acid residue bonded at its amino group .
An alkyl group is a branched or unbranched Cx to C6 alkyl or benzyl, and aryl is a substituted or unsubstituted C6 to C14 carbocyclic or heterocyclic aromatic having one or two rings. A substituted aryl is an aryl bearing one or more ^ to C6 substituents including alkyl, alkoxy, or acyl groups, or halogen, hydroxy, amino, or amido groups. A substituted amino is an amino group having one or two branched or unbranched Cλ to C6 alkyl or benzyl groups. A Michael acceptor (e.g., H2C=CH-C (=0) - , and related unsaturated groups) is a group that undergoes conjugate addition with a nucleophile.
Preferably, Rx is halogen, alkyl sulfonate, carboxylate, or aryl sulfonate and R2 is hydroxy, amino, alkylamino, ammonium, or alkyl ammonium, or together Rx and R2 are O, NH2\ or NH; X is a C2 to C4 alkyl; R3 is H;
R4 is -NH-W, where W is an amino acid residue bonded at its carbonyl group or a peptide moiety bonded at its terminal carbonyl group; and R5 is a -C(=0)-Y', where Y' is a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group.
In preferred embodiments, W is an amino acid residue bonded at its carbonyl group and Y' is a peptide moiety bonded at its terminal amino group. In other preferred embodiments, Rx is alkyl sulfonate and R2 is an ammonium, or together R: and R2 are 0, or NH; X is C„ alkyl; and the amino acid residue is a glycine residue.
In preferred embodiments, a portion of the peptide moiety is identical to a portion of a selected peptide or an antigenic peptide. The peptide moiety can preferably contain between 2 and 10 amino acid residues. Most preferably, the compound is G(az)IDKPILK or G (az) AFVTIGK, where (az) is an unnatural amino acid residue where the side chain is a C6 alkyl having a terminal aziridine group . A further aspect of this invention relates to a method of forming a ligand-protein complex. The method includes the steps of providing a protein having an arginine-specific binding region, the binding region including a nucleophilic residue, and adding a ligand to bind with the protein at the arginine-specific binding region, the ligand having a moiety which reacts with the nucleophilic residue. The moiety of the ligand and the nucleophilic residue of the protein form a covalent bond between the ligand and the protein. In preferred embodiments, the arginine-specific binding region includes a thiol , a thiol and a carboxyl , or two carboxyl groups, and the moiety is halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, carboxylate, a Michael acceptor, aziridine, or epoxide. Most preferably, the arginine-specific binding
region includes a thiol and a carboxyl and the moiety is aziridine, or epoxide.
In other preferred embodiments, the step of providing the protein includes the step of altering a binding region of the protein to introduce the arginine- specific binding region.
Another aspect of this invention relates to a covalently linked ligand-protein complex including a protein having an arginine-specific binding region and a ligand covalently bonded to the binding region of the protein, said ligand having the formula
where one of Rλ and R2 is hydroxy, alkyl, alkyl carbonyl, amino, alkyl amino, ammonium, or alkyl ammonium, and the other of Rx and R2 is the covalent bond to the protein; X is Cx to C6 alkyl, substituted aryl, or deleted; R3 is H, alkyl, or aryl; R4 is alkyl, aryl, -NH-W, or -C(=0)-Y, where W is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group; and R5 is H, alkyl, aryl, -NH-W', or -C(=0)-Y', where W' is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y' is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide
moiety bonded at its terminal amino group, or an amino acid residue bonded at its amino group.
In preferred embodiments, the arginine-specific binding region includes a thiol, a thiol and carboxyl, or two carboxyl groups; Rx is the covalent bond between the ligand and the protein; R2 is hydroxy, alkyl, alkyl carbonyl, amino, alkyl amino, ammonium, or alkyl ammonium; R3 is H; and X is a C2 to C4 alkyl. Most preferably, R2 is the covalent bond between the ligand and the protein (i.e., a thioether or ester linkange) . The invention includes one or more of the following advantages. The ligand selectively reacts with groups in the binding region of the protein. Thus, undesired reactions outside of the binding region are unlikely to occur. In addition, the covalent nature of the linkage between the ligand and the protein changes the kinetics of ligand binding dramatically by making the ligand binding essentially irreversible.
A "selected peptide" is any peptide or variant thereof that is associated with an undesired physical condition, such as, but not limited to, an immune system- selective peptide (i.e., a peptide that induces an immune response) . Note that "an antigenic peptide" mentioned herein can be either a naturally occurring peptide or a variant thereof (e.g., containing an acetylated alpha- amino group, an amidated alpha-carboxyl group, a D- and/or beta- or gamma-amino acid residue, or any suitable organic moiety) ; indeed, there are only two criteria, i.e., it is a peptide and it binds to a class I or class II MHC molecule in the manner described in Stern, L.J. & Don C. Wiley, Structure (1994) 2, 245-251.
Other features or advantages of the present invention will be apparent from the following drawings and detailed description of representative examples.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a schematic diagram depicting the synthesis and structure of a compound according to the invention. Fig. 2 is a drawing of a model of the P2 pocket of HLA-B27 binding arginine (Fig. 2A) , a model of an aziridine-containing ligand (Fig. 2B) and a covalently bonded residue (Fig. 2C) .
Fig. 3 is a graph of three HPLC runs depicting the stability of the aziridine ligand to free thiols in solution.
Fig. 4 is an image of an SDS-PAGE (15%) of HLA-B27 complexed with the aziridine-containing peptide (G(az) IDKPILK) (lane 1) and the control peptide (GRIDKPILK) (lane 2) .
DETAILED DESCRIPTION OF THE INVENTION Ligands bind to proteins according to particular kinetic profiles. Short peptides containing arginine at peptide position 2 (P2) bind to arginine-specific binding regions of class I major histocompatibility complex (MHC) glycoproteins, such as HLA-B27. The HLA-B27/peptide complex is recognized by particular T cells. This recognition leads to both the development of the repertoire of T cells in the cellular immune system and the activation of cytotoxic T cells. The reversible kinetics of binding lead to release of the ligand from the binding site, thereby affecting the recognition of the ligand-protein complex. By changing the kinetics of the reversible binding, it is possible to alter the response to the cellular immune system. Reactive ligands can be used to change the kinetics of binding by reacting with the protein when bound.
Suitable reactive ligands for changing the kinetics of binding with protein substrates are compounds
of the formula I. Each of Rx and R2, independently, is hydroxy, halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, carboxylate, a Michael acceptor, amino, alkylamino, ammonium, or alkyl ammonium. Alternatively, together Rλ and R2 are O, NH, NH2 +, or NZ, where Z is alkyl, or aryl, thus forming an epoxide, aziridine or substituted aziridine ring. X, a spacer group, is Cx to C6 alkyl, substituted aryl, or deleted. R3 is H, alkyl, or aryl. R4 is alkyl, aryl, -NH-W, or -C(=0)-Y, where W is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group. R5 is H, alkyl, aryl, -NH-W', or -C(=0)-Y', where W' is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y' is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group, or an amino acid residue bonded at its amino group.
In particular, one of Rx and R2 is a reactive group that will react with a nucleophile (e.g., -SH, -NH2, -OH, or -COO") . Thus, one of the groups is a leaving group or contains a leaving group. The leaving group can be a halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, alkyl carboxylate, ammonium, alkyl ammonium, epoxide, aziridine, or substituted aziridine, where the alkyl group is a branched or unbranched Cx to C6 alkyl or benzyl and aryl is a substituted or unsubstituted C5 to C14 carbocyclic or heterocyclic aromatic having one or two rings. Alternatively, Rx and R2 is a Michael acceptor (e.g., H2C=CH-C (=0) -, and related unsaturated groups) which undergoes conjugate addition with a nucleophile. The
reactions between the group at Rx or R2 and the nucleophile take place at a binding region of a protein.
The compounds of the invention can be used to prepare reactive ligands, or are themselves reactive ligands that can be used to make covalent ligand-protein complexes in vi tro or in vivo . At R4 and R5, is a reactive group or the peptide moiety or amino acid residue is ultimately a group that binds selectively to a protein. In particular, a portion of the peptide moiety, the amino acid residue, or a combination thereof is a selected peptide or an antigenic peptide, which can be either a naturally occurring peptide or a variant thereof (e.g., containing an acetylated alpha-amino group, an amidated a-carboxyl group, a D- and/or beta- or gamma- amino acid residue, or any suitable organic moiety) . In particular, a portion of the peptide moiety, the amino acid residue, or their combination, is a peptide and it binds to a class I or class II MHC molecule in the manner described in Stern, L.J. & Wiley, D.C., Structure (1994) 2, 245-251. For example, short peptides containing arginine at peptide position 2 (P2) bind to arginine- specific binding regions of class I major histocompatibility complex (MHC) glycoproteins, such as HLA-B27. The HLA-B27/peptide complex is recognized by particular T cells.
Fig. 1 is a schematic diagram depicting the synthesis and structure of a compound according to the invention. Abbreviations are Boc, butoxycarbonyl ; Ph, phenyl; DEAD, diethyl azodicarboxylate; THF, tetrahydrofuran; DMS, dimethyl sulfide; TFA, trifluoroacetic acid; Gly, glycine; BOP, benzotriazol-1- yloxy-tris (dimethylamino)phosphonium hexafluorophosphate; HOBT, 1-hydroxybenzotriazole; DIEA, diisopropyl ethylamine; MCPBA, m-chloroperoxybenzoic acid; EtOAc, ethyl acetate; Ms, mesyl ; Me, methyl; HBTU 2-(lH-
benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate; and DMF, dimethylformamide .
The first two steps shown in Fig. 1 can be modified to prepare variants of Compound 1, where the length of the alkenyl group can be varied, or other functionalities can be added using ordinary synthetic methods. Boc-amine (Compound 1) was prepared according to the methods described in Arnold, L.D., Kalantar, T.H. & Vederas, J.C. (1985) J. Am. Chem. Soc. 107, 7105-7109, and Arnold, L.D., Drover, J.C. G. & Vederas, J.C. (1987) J. Am. Chem. Soc. 109, 4649-4659 and the dipeptides were prepared according to the methods described in Arnold, L.D., Kalantar, T.H. & Vederas, J.C. (1985) J. Am. Chem. Soc. 107, 7105-7109, and Arnold, L.D., Drover, J.C.G. & Vederas, J.C. (1987) J. Am. Chem. Soc. 109, 4649-4659. The olefinic group of Compound 1 can be transformed by ordinary methods, e.g., addition reactions. The subsequent reactions of Compound 1 and its analogues can be carried out to link other natural or unnatural amino acid residues or peptide moieties.
A ligand-protein complex is formed by exposing a protein having an arginine-specific binding region which includes a nucleophilic residue to a ligand which binds with the protein at the arginine-specific binding region. The ligand is a compound of the invention, thus having a moiety which reacts with the nucleophilic residue. Upon binding, the reactive moiety of the ligand and the nucleophilic residue of the protein form a covalent bond between the ligand and the protein, resulting in a covalently linked ligand-protein complex where the protein and ligand become linked at Rx or R2, changing the kinetics of release of the ligand from the binding site. As an example, this influences the recognition of the ligand-protein complex by the cellular immune system, making it possible to alter immune responses.
Cytotoxic T-lymphocytes (CTLs) recognize antigens as short peptides bound to MHC class I molecules that consist of a heavy chain (H) and 32-microglobulin (β2 -m) . For a review of CTLs, see Germain, R.N. & Margulies, D.H. (1993) A. Rev. Immun. 11, 403-450. The structure of HLA- B27 is known. See, Madden, D.R., Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1991) Nature 353, 321- 325, Gorga, J.C, Madden, D.R., Prendergast , J.K., Wiley, D.C. & Strominger, J.L. (1992) Proteins 12, 87-90, and Madden, D.R., Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1992) Cell 70, 1035-1048.
The involvement of HLA-B27 has been implicated in, for example, the autoimmune disorder ankylosing spondylitis. See, Brewerton, D.A., Caffrey, M., Hart, F.D., James, D.C.O., Nicholls, A. & Sturrock, R.D. (1973) Lancet 1, 904-907, Schlosstein, L. , Terasaki, P.I., Bluestone, R. & Pearson, CM. (1973) N. Engl . J. Med. 288, 704-706, and Hammer, R.E., Maika, S.D., Richardson, J.A., Tang, J.-P. & Taurog, J.D. (1990) Cell 63, 1099- 1112. The autoimmune response involves binding of an autoantigen peptide by HLA-B27. Endogenous and viral peptides that bind to HLA-B27 have an arginine in their P2 position, as described by Jardetzky, T.S., Lane, W.S., Robinson, R.A. , Madden, D.R. & Wiley, D.C. (1991) Nature 353, 326-329. The d-guanidinium group of the arginine is bound within a deep pocket where four polymorphic residues project toward it. See, Madden, D.R., Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1991) Nature 353, 321-325, and Madden, D.R. , Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1992) Cell 70, 1035-1048.
Activation of T cell receptors on CD8+ and CD4+ T cells requires the recognition of antigenic peptides bound in the groove of MHC molecules on the surface of antigen-presenting cells. Antigenic peptides bind in an extended conformation to class I and class II MHC
molecules. X-ray crystallography studies have revealed that for all class I MHC complexes, the peptide N- and C- termini form hydrogen bonds with conserved MHC amino acid residues located at both ends of the binding site, some peptide side chains are buried in deep pockets along the binding site, and the central region of the peptide arch away from the floor of the binding site with side chains generally pointing toward T cell receptors. Antigenic peptides of 8- to 10-amino acids long have been shown to adopt this mode of binding. A decamer has been shown to extend out of the binding groove at the C-terminus and an octamer has been shown to preferentially leave the N- terminal end of the binding site unoccupied. On the basis of these observations, other modes of binding can be described: extension of a decamer out of the N- terminal end of the binding site and binding of an octamer preferentially at the N-terminal end of the groove leaving the C-terminal end of the groove unoccupied. In contrast to class I MHC molecules, class II MHC molecules bind to longer antigenic peptides. This difference in length can be ascribed to structural differences between the two binding sites and the position of key MHC amino acid residues that interact with the peptide backbone. The few X-ray structures of class II MHC complexes that have been determined so far indicate that the antigenic peptide is stretched out along most of its length and adopts a bound conformation characteristic of a type II polyproline helix. The peptide' s N- and C-termini extend out of the binding groove. Side chains of some amino acid residues bind specifically in pockets made of polymorphic MHC amino acid residues while other side chains, spaced approximately three amino acid residues apart, point away from the binding site.
Interaction of T cell receptors with both types of MHC complexes involves amino acid residues on both the peptide and MHC molecules. For class I MHC complexes, amino acid residues from the central portion of the peptide, where side chains are most exposed, play a more crucial role in this recognition event, whereas for class II MHC complexes, amino acid residues having side chains pointing up are found along the entire sequence. In designing peptides of this invention, it is preferable to select as anchor amino acid residues those residues with side chains pointing toward T cell receptors.
References for the structures of class I MHC molecules include: Madden, D.R., Garboczi, D.N. & Wiley, D.C. (1993) Cell 75, 693-708; Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., Strominger, J.L. & Wiley, D.C. (1987) Nature 329, 506-512; Madden, D.R., Gorga, J.C, Strominger, J.L. & Wiley, D.C. (1991) Nature 353, 321-325; Silver, M.J., Guo, H.-C, Strominger, J.L. & Wiley, D.C. (1992) Nature 360, 367-369; Guo, H.-C, Jadertzky, T.S., Garrett, T.P.J., Lane, W.S., Strominger,
J.L. & Wiley, D.C (1992) Nature 360, 364-366; and
Madden, D.R., Gorga, J.C, Strominger, J.L. & Wiley, D.C.
(1992) Cell 70, 1035-1048. References for the structures of class II MHC molecules include Brown, J.H. , Jardetzky, T.S., Gorga, J.C, Stern, L.J., Urban, R.G., Strominger, J.L., and Wiley, D.C. (1993) Nature 364, 33-39; Stern L.J. and Wiley, D.C. (1994) Structure 2, 245-251; and Stern, J.L., Brown, J.H. , Jardertzky, T.S., Gorga, J.C, Urban, R.G., Strominger, J.L., and Wiley, D.C. (1994) Nature 368, 215-221.
According to the structural model of the binding site shown in Fig. 2A, His-9, Thr-24, Glu-45, and a bound water form a hydrogen bond network with the guanidinium group of the ligand. The P2 pocket of HLA-B27 forms a planar network of hydrogen bonds to the guanidinium group
of arginine at P2 of a bound peptide. Perpendicular to the planar network of hydrogen bonds, the free thiol of Cys-67 is separated from the guanidinium group by about 3.7 A. The sulfhydryl group of Cys-67 is located directly above the plane of the guanidinium group of the ligand.
The arrangement of protein side chains (amino acid residues) suggested that it might be possible to induce the pocket to act as an enzyme active site, by designing a suitable substrate. A ligand was synthesized with a reactive side chain designed to mimic arginine. Although other reactive groups at this position can be used, an aziridine is most preferred. The reactive ligand contains an aziridine and binds covalently by reaction of the aziridine upon binding in the arginine-specific P2 pocket of HLA-B27. A peptide was designed such that a covalent bond with HLA-B27 will form between the ligand and the protein spontaneously and selectively upon binding. An aziridine-containing amino acid mimic of arginine was selected (Fig. 2B) . According to Fig. 2B, the aziridine-containing ligand can bind in place of the guanidinium group with the aziridine amine, forming a hydrogen bonded salt bridge to Glu-45. In this model with one diastereomer of the aziridine depicted, the free thiol of Cys-67 is poised for in-line nucleophilic attack of the aziridine group.
Fig. 2C shows the expected geometry of the covalent complex between Cys-45 and the aziridine- containing peptide that results from the nucleophilic attack of the thiol which opens the aziridine group. The positively charged secondary amine of the aziridine ring is expected to form a hydrogen-bonded charged-pair with Glu-45 in the arginine-specific pocket, positioning the eta-carbon of the aziridine ring for an in-line, ring- opening attack by the thiolate of Cys-67 (Fig. 2C) .
Selectivity is expected from the polarizability of the aziridine by Glu-45 and the propinquity of the Cys-67 thiol to the bound aziridine ring.
Using tryptic digestion followed by mass spectrometry and amino acid sequencing, the aziridine- containing ligand is shown to alkylate specifically cysteine 67 of HLA-B27. Neither free cysteine in solution nor an exposed cysteine on a class II MHC molecule can be alkylated, showing that specific recognition between the anchor side-chain pocket of an MHC class I protein and the designed ligand (propinquity) is necessary to induce the selective covalent reaction with the MHC class I molecule.
The aziridine within the ligand was cyclized from the mesylate in solution, before addition to the folding buffer containing recombinantly expressed, purified HLA- B27 heavy chain and β2-m.
In general, conservative residue substitutions in the middle portion of antigenic peptides of T cells are introduced to selectively inhibit activation of T cells without significantly altering binding affinity to the relevant MHC molecules. See, Sloan-Lancaster, J. , Evavold, B.D. & Allen, P.M. (1993) Nature 363, 156-159; De Magistris, M.T., Alexander, J., Coggeshall, M. , Altman, A., Gaeta, F.C.A., Grey, M.H. & Sette, A. (1992) Cell 68, 625-634; and Alexander, J. , Snoke, K. , Ruppert, J., Sidney, J., Wall, M. , Southwood, S., Oseroff, C, Arrhenius, T., Gaeta, F.C.A., Colon, S.M., Grey, H.M. & Sette, A. (1993) J. Immunol. 150, 1-7. Activation and regulation of immune responses (e.g., autoimmune responses, responses to viral infection, and responses to cancerous cells) can be influenced by the compounds of the invention, since the compounds bind to specific protein binding pockets irreversibly. It is possible to activate T cell responses by treatment with a preformed
ligand-protein complex or by treatment with the reactive ligand or a precursor thereof.
Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications disclosed herein are incorporated by reference. The specific examples set forth below are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Ligand Synthesis
Nonamer peptides containing the aziridine were synthesized by coupling the dipeptide to synthetic heptamers corresponding to the seven C-terminal amino acids of two peptides known to bind to HLA-B27, GRIDKPILK and GRAFVTIGK. See, Jardetzky, T.S., Lane, W.S., Robinson, R.A. , Madden, D.R. & Wiley, D.C. (1991) Nature 353, 326-329. The peptide sequence of the ligand shown in Fig. 1 and described here is based upon a ribosomal peptide GRIDKPILK. Other peptide sequences and analogues can be substituted in the scheme shown in Fig. 1 to afford other reactive ligands. Diastereomers of the aziridine were unresolved. All reactions followed standard laboratory practices. All intermediates and products were characterized by XH NMR, 13C NMR, IR and fast atom bombardment mass spectrometry (FAB MS) .
Boc-amine (Compound 1) . Boc-amine Compound 1 was prepared according to the methods described in Arnold, L.D., Kalantar, T.H. & Vederas, J.C (1985) J. Am. Chem. Soc. 107, 7105-7109, and Arnold, L.D., Drover, J.C.G. & Vederas, J.C. (1987) J. Am. Chem. Soc. 109, 4649-4659.
Boc-Glycine- (2-amino-hept-6-enoic acid) dipeptide methyl ester (Compound 2) . To a solution of Compound 1 (211 mg, 0.911 mmol) in 5.0 mL of CH2C12 was added 5.0 mL of trifluoroacetic acid. The mixture was swirled, allowed to stand for 20 minutes, diluted with 4 mL of toluene, and concentrated in vacuo to afford the crude deprotected amine. The deprotected amine was dissolved in 5.0 mL of CH2C12. Diisopropyl ethylamine (0.476 mL, 0.273 mmol) was added to the solution containing the deprotected amine, followed by Boc-glycine (175 mg, 1.00 mmol) and benzotriazol-1-yloxy- tris (dimethylamino)phosphonium hexafluorophosphate (442 mg, 1.00 mmol) . The mixture was stirred for 6 hours and then quenched by adding 5 drops isopropyl amine. The mixture was concentrated in vacuo and chromatographed (40% ethyl acetate :hexanes) to give 178 mg (0.542 mmol, 59%) of Compound 2.
Epoxy Dipeptide (Compound 3) . To a solution of Compound 2 (145 mg, 0.441 mmol) in 7.0 mL of CH2C12 was
added m-chloroperoxybenzoic acid (91.4 mg, 0.529 mmol) . The mixture was stirred for 9 hours and then diluted with 40 mL of ethyl acetate, washed with 10% aqueous NaS20s (20 mL) , washed with saturated NaHC03 solution (2 x 20 mL) , washed with brine (10 mL) , dried over MgS04, concentrated in vacuo, and chromatographed (60% ethyl acetate ihexanes) to give 91.0 mg (0.264 mmol, 50%) of epoxy dipeptide Compound 3.
Compound 3 was characterized by: IR (Film) : n 2934, 1744, 1719, 1678, 1524, 1456, 1437, 1412, 1391, 1368, 1250, 1211, 1171, 1051, 1030, 939, 864, 835, 781, 615 cm"1; *H NMR (CDC13) : d 1.41 (s) , 1.48 (m) , 1.52 (m) , 1.62 (m) , 1.82 (m) , 2.40 (q) , 2.69 (t) , 2.84 (t), 3.69 (s) , 3.78 (m) , 4.57 (q) , 5.26 (d) , 6.71; and 13C NMR (CDC13) : d 24.82, 25.32, 25.38, 28.16, 31.94, 44.10, 46.77, 51.87, 51.96, 52.20, 79.92, 156.02, 169.41, 172.59.
Azido Dipeptide (Compound 4) . To a solution of Compound 3 (66.0 mg, 0.191 mmol) in 5.0 mL of a 9:1 methanol :water mixture was added NH4C1 (80 mg, 1.49 mmol) and NaN3 (300 mg, 4.61 mmol) . The mixture was heated to reflux and stirred for 2 hours. The mixture was then cooled to 25°C, diluted with 40 mL of ethyl acetate, washed with water (2 x 20 mL) , washed with brine (10 mL) dried over MgS04, and concentrated in vacuo to give 71.0 mg (0.191 mmol, 100%) of azido dipeptide Compound 4.
Compound 4 was characterized by: IR (Film) : n 3328, 2976, 2936, 2865, 2101, 1742, 1671, 1524, 1439, 1393, 1368, 1279, 1252, 1217, 1167, 1051, 1030, 941, 864, 632 cm"1; LH NMR (CDCl3) : d 1.28 (m) , 1.38 (s) , 1.61 (m) , 1.79 (m) , 1.82 (d) , 3.17 (m) , 3.24 (m) , 3.66 (s) , 3.74 (m) , 4.52 (m) , 5.49 (t) , 6.90 (d) ; and 13C NMR (CDC13) : d 24.60, 24.72, 24.82, 28.19, 32.01, 33.80, 44.09, 51.75, 51.89, 52.34, 56.86, 64.84, 70.12, 70.38, 80.18, 156.16, 169.59, 172.72. Boc-amine Dipeptide (Compound 5) . A 5% solution of Pd on carbon in ethyl acetate (6.0 mL) was stirred at room temperature, under atmospheric pressure of hydrogen gas, for one hour. Addition of Compound 4 (82.3 mg, 0.24 mmol) and Boc-anhydride (104.3 mg, 0.48 mmol) required 1.0 mL ethyl acetate, followed by two ethyl acetate washes of 1.0 mL each. After stirring 12 hours, and Celite was added. The solution was filtered and concentrated in vacuo . The residue was purified by flash chromatography, running neat ethyl acetate, to yield 86.6 mg (0.188 mmol, 78%) of Boc-amine dipeptide Compound 5.
Compound 5 was characterized by: IR (Film) : n 3328, 2978, 2934, 2865, 1744, 1686, 1524, 1456, 1439, 1412, 1393, 1368, 1275, 1250, 1169, 1051, 1030, 864, 781, 735 cm"1; Η NMR (CDC13) : d 1.39 (s) , 1.41 (s) , 1.48 (t) , 1.64 (m) , 1.81 (m) , 2.92 (m) , 3.22 (br s) , 3.60 (d) , 3.69 (s) , 3.77 (d) , 4.55 (m) , 5.13 (br s) , 5.43 (d) , 6.86 (br s) ; and 13C NMR (CDC13) : d 24.56, 24.73, 24.95, 28.08, 31.71, 33.90, 43.82, 46.35, 51.75, 52.15, 70.38, 70.63, 79.06, 79.84, 156.11, 156.56, 169.76. Mesylate Dipeptide Methyl Ester (Compound 6) .
Compound 5 (96.0 mg, 0.208 mmol) was weighed into a pear shaped flask and azeotroped with xylenes, before being dissolved in dry methylene chloride (3.5 mL, 0.06 M) . After cooling to 0°C, mesyl anhydride (174.2 mg, 0.312 mmol) was added. Approximately 20 minutes later, the reaction was complete and was quenched by the addition of water. Excess ethyl acetate was added. The organic phase was washed with 5% aqueous HCl , saturated aqueous sodium bicarbonate, and brine. Following drying over MgS04, the mesylate dipeptide methyl ester Compound 6 was isolated in vacuo .
NHBoc
Mesylate Dipeptide Carboxylic Acid (Compound 7) .
Compound 6 was dissolved in methanol (0.56 mL) and tetrahydrofuran (2.25 mL) , and cooled to 0°C. An aqueous
solution of IN LiOH (0.56 mL) was added, and the reaction was stirred for half an hour. The reaction was quenched by the addition of excess ethyl acetate and IN aqueous HCl (0.59 mL) . The organic phase was isolated in vacuo and azeotroped with xylenes to afford the mesylate dipeptide carboxylic acid Compound 7.
NHBoc
Mesylate Polypeptide (Compound 8). Compound 7, prepared in the step above, was added in N-methyl pyrrolidone to Wang resin coupled to the sequence 0 H2N-IDKPILK. 1-Hydroxybenzotriazole (61.2 mg, 0.4 mmol), 2- (lH-benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate (83.4 mg, 0.22 mmol), and Hunig's base (0.061 mL, 0.47 mmol) were added, and the resin was shaken for one hour at room temperature to give the 5 resin-bound mesylate polypeptide. The polypeptide was cleaved from the resin using 95% trifluoroacetic acid in water to afford the mesylate polypeptide Compound 8. Compound 8 was purified by reverse phase HPLC, running a gradient from 85:15 to 50:50 (water with 0.1% 0 trifluoroacetic acid:methanol) . Mass spectrometry confirmed the identity of Compound 8 (MH+ 1133) .
1. H2N-IDKPILK-Resin
HBTU / HOBT
DIEA
DMF
2. 2. 95 % TFA
Aziridine Polypeptide (Compound 9) . Compound 8 was treated with sodium hydroxide (10 equivalents at room temperature for half an hour) , or lithium hydroxide in methanol, to afford aziridine polypeptide Compound 9. Mass spectrometry confirmed the identity of Compound 9 (MH+ 1055) . Additionally, Compound 9 was subjected to
Edman degradation and microsequencing, which confirmed its composition to be G (az) IDKPILK, where (az) is the unnatural aziridine amino acid residue.
The polypeptide G(az)AFVTIGK was prepared using a different resin-bound peptide. The aziridine within a peptide was cyclized from the mesylate in solution before addition to the folding buffer containing recombinantly expressed, purified HLA-B27 heavy chain and jS2-m.
8
LiOH MeOH
Specificity of the Aziridine-containing Ligand for HLA-B27. The selectivity of the aziridine-containing peptide for the free thiol on HLA-B27 was demonstrated in three ways .
First, neither the aziridine-peptide nor its mesylate precursor reacted with a 200 molar equivalent excess of the amino acid components of the P2 binding pocket: the free amino acids cysteine, threonine, or glutamic acid. To 950 mL of HLA-B27 folding buffer, the unprotected amino acids cysteine, threonine and glutamic acid were added each to a final concentration of 20 mM. 220 mg of mesylate Compound 8 was made basic in 50 mL methanol by the addition of 2 mL IN NaOH. After 15 minutes, the solution contained approximately equimolar distributions of mesylate precursor Compound 8 and aziridine-containing ligand Compound 9 (verified by reverse phase HPLC) and the solution was added to the folding buffer (both Compound 8 and Compound 9 have a final concentration of 0.1 mM in the folding buffer), which was incubated at 10°C After half an hour and approximately every 12 hours later, 100 mL of the folding buffer was removed and subjected to reverse phase HPLC, running a gradient of 100:0 to 40:60 (0.1% trifluoroacetic acid in water : acetonitrile) over 30 minutes and monitoring at 214 nm.
Elution profiles of reverse phase HPLC after designated incubation times show constant levels of the aziridine and mesylate containing peptides, as shown in Fig. 3. The reactivity was accessed in a time course experiment over three days. The stabilities of the ligands (Compound 8 and Compound 9) were established in aqueous solution over that time period, although a small fraction of the mesylate (Compound 8) gradually converted to the aziridine (Compound 9) . The aziridine-nonameric-
peptide (G(az) IDKPILK) and its mesylate precursor are stable and do not react with free cysteine, threonine, or glutamic acid. The unprotected amino acids cysteine, threonine, and glutamic acid (each present in 200-fold molar excess) were incubated with equal molar amounts of the aziridine-containing ligand and its mesylate precursor in the HLA-B27 folding buffer containing reduced glutathione (50-fold molar excess of free thiol) . Over three days, the sum of the mesylate precursor and aziridine-containing ligand remained approximately the same. No degradation or reaction products of the aziridine or mesylate were observed. Peaks at 15.63 and 16.05 minutes correspond to the aziridine-containing ligand and its mesylate precursor, respectively, other peaks belong to the folding buffer. Peaks were assigned by injection of standards or FAB-MS. The ordinate is proportional to absorbance with arbitrary units.
Second, the aziridine-containing-peptide failed to alkylate the free cysteine residue in the peptide-binding groove of the class II MHC molecule HLA-DR1. See, Stern, L.J. & Wiley, D.C. (1992) Cell 68, 465-477. Following standard peptide loading procedures for class II MHC molecules described in Stern, L.J. & Wiley, D.C. (1992) Cell 68, 465-477, empty, folded HLA-DR1 was incubated at 37°C with an eighteen fold molar excess of the aziridine- containing-peptide, G (az) IDKPILK, Compound 9. Aliquots of the mixture were removed daily for 3 days, denatured in 6M guanidine hydrochloride, and tested for the presence of free thiol using Ellman's reagent. The portion of HLA-DR1 containing the only free cysteine, Cys-30, does not bind arginine and lacks the glutamate and threonine of the arginine binding pocket in HLA-B27 (see, Stern, L.J., Brown, J.H. , Jardetzky, T.S., Gorga, J.C, Urban, R.G. , Strominger, J.L. & Wiley, D.C. (1994) Nature 368, 215-221), nevertheless it represents a
free thiol accessible on the surface of a protein. The free thiol of Cys-30 remained unalkylated and its concentration was constant, throughout the course of the experiment. As a control the addition of one molar equivalent of iodoacetic acid to the denatured HLA-DR1, after 2 hours, was shown to decrease measured amounts of free thiol by greater than 50%, demonstrating that the response to Ellman's reagent was due to the presence of a free thiol . Third, the aziridine ligand alkylates Cys-67 during the folding of recombinant HLA-B27 despite a 5000 molar equivalent excess of cysteine in the glutathione of the refolding buffer. Each complex was folded by incubation at 10°C of HLA-B27 heavy chain (1 mM) and β2- (2 mM) in a N2 (g) sparged solution of 20 mM TES (pH = 8.0), 0.2 M L-arginine (pH = 8.0), 2 mM Na2EDTA, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, and 20 mM ligand. The ligand was described in Garboczi, D. N. , Hung, D. T. & Wiley, D. C (1992) Proc . Natl. Acad. Sci . USA 89, 3429-3433. Yields of the complex were sometimes enhanced with rigorously anaerobic folding conditions.
Gel filtration HPLC with a running buffer of 150 mM NaCl, 50 mM Tris (pH = 8.0) was used to purify folded HLA-B27 complexes from aggregates and excess jS2-m. Folded complexes had a retention time consistent with their molecular weight of 44 kD. Lower yields were consistently obtained with the aziridine ligand Compound 9; typical yields, confirmed by amino acid analysis, were approximately 60% or less than yields obtained with the control peptide (GRIDKPILK) . The lower yields might result from less efficient hydrogen bonding to the aziridine moiety compared to the planar guanidinium group of the control peptide, or decreased reactivity of one diastereomer of the aziridine ligand Compound 9 (kinetic resolution) .
As in previous folding studies of recombinant class I MHC molecules (Garboczi, D.N., Hung, D.T. & Wiley, D.C. (1992) Proc . Natl . Acad. Sci . USA 89, 3429- 3433) , the folding of HLA-B27 was dependent upon a peptide ligand, in this case containing aziridine (Compound 9) . HLA-A2 , an MHC molecule lacking specificity for arginine at P2 , failed to fold in the presence of the aziridine-containing peptide, as expected. Characterization of Covalent Ligand-Protein Bond. The aziridine-containing ligands were shown to form covalent bonds with HLA-B27 by a shift in mobility of the heavy chain on SDS-PAGE; reaction with Cys-67 was shown by tryptic digestion, mass spectrometry (MS) , and Edman microsequencing.
In all preparations of the MHC class I complex based on the aziridine-containing ligand Compound 9, there was an additional SDS-PAGE band corresponding to unmodified heavy chain. This band became more prominent with decreasing concentrations of the aziridine- containing ligand Compound 9 in the folding buffer and low yields of MHC class I molecules, suggesting that the band is due to empty MHC class I molecules.
Fig. 4. depicts the results of an SDS-PAGE (15 %) of HLA-B27 complexed with the aziridine-containing peptide (G(az) IDKPILK (lane 1) and the control peptide (GRIDKPILK) (lane 2) . The SDS-PAGE of HLA-B27 complexed with aziridine-peptides revealed a mobility shift of the heavy chains of the complex due to addition of the aziridine-containing ligand (Fig.4, lane 1), when compared to heavy chain from complexes with the same peptides with arginine in the P2 position (Fig. 4, lane 2) . The mobility of /32-m remained unchanged.
In order to identify the alkylated amino acid, the aziridine-modified complex was digested with trypsin and
the fragments separated by reverse phase HPLC. The carboxyamidomethylated tryptic peptides were separated by narrow-bore HPLC using a Vydac C18 2.1 x 150 mm reverse phase column on a Hewlett-Packard 1090 HPLC/1040 diode array detector. Putative difference peaks from the chromatogram were chosen based on differential UV absorbance at 210, 277, and 292 nm. These were further screened by matrix-assisted laser desorption time-of- flight spectrometry (MALDI-MS) on a Finnigan Lasermat 2000 (Hemel, England), and submitted to Edman microsequencing on an Applied Biosystems 477A (Foster City, CA) . Details of strategies for the selection of peptide fractions and their microsequencing have previously been described by Lane, W.S., Galat, A., Harding, M.W. & Schreiber, S.L. (1991) J. Prot. Chem. 10, 151-160. Microcapillary HPLC/electrospray ionization/tandem mass spectrometry on a Finnigan TSQ7000 triple quadrupole mass spectrometer (San Jose, CA) as described in Hunt, D. F., Henderson, R.A. , Shabanowitz, J., Sakaguchi, K. , Michel, H., Sevilir, N. , Cox, A.L., Appella, E. & Engelhard, V.H. (1992) Science 255, 1261- 1263.
The chromatogram of the proteolyzed fragments was compared with a tryptic digest of the MHC class I protein formed with the arginine-containing parent-peptide
(GRIDKPILK) . Matrix-assisted laser desorption time-of- flight (MALDI) MS was used to screen rapidly putative difference peaks, which were deficient in UV absorbance at 277 and 292 nm (lacking tyrosine and tryptophan) . A fraction was found with a singly charged ion (MH+) of the expected mass (m/z = 1759) of the tryptic fragment resulting from alkylation of Cys-67 by the aziridine- containing ligand. Edman microsequencing revealed this fraction to contain the peptide ligand in equimolar amounts with the HLA-B27 heavy chain fragment containing
Cys-67. Consistent with the specific alkylation of Cys- 67 by the aziridine, no PTH derivatives were observed at either the sequence position of the aziridine-amino acid in the peptide or Cys-67 in the heavy chain. Microcapillary LC electrospray mass spectrometry (LC-
ESIMS) (11, 12) further confirmed the expected mass of the aziridine-modified fragment (m/z=879.8 M2H++) .
Stability of Covalent MHC-peptide Complexes. The thermodynamic stability of the class I MHC molecules from mouse and human have been shown to depend on the sequence of the bound peptide. See, Bouvier, M. & Wiley, D.C. (1994) Science 265, 398-402, Fahnestock, M.L., Tamir, I., Narhi, L.O. & Bjorkman, P.J. (1992) Science 258, 1658- 1662, and Fahnestock, M.L., Johnson, J.L., Renny Feldman, R.M. , Tsomides, T.J., Mayer, J. , Narhi, L.O. & Bjorkman, P.J. (1994) Biochemistry 33, 8149-8158. The thermal transition of the HLA-B27 complexes was measured using circular dichroism (CD) .
An Aviv 62DS (Lakewood, NJ) equipped with thermoelectric temperature controller was used to obtain thermal denaturation curves in triplicate, from 25-95 'C, as described in Bouvier, M. & Wiley, D.C. (1994) Science 265, 398-402. The addition of 50 mM NaCl to the typical 10 mM MOPS (pH = 8.0) buffer was found to prevent aggregation of HLA-B27. The additional salt had no effect on the measured melting temperature (Tm) of the HLA-A2 complex formed with a hepatitis B-derived peptide.
The covalent complexes of HLA-B27 with two aziridine-containing-peptides, G(az) IDKPILK (Compound 9) and G (az) AFVTIGK, both denature at approximately the same temperature, 62 °C G(az) AFVTIGK was prepared by coupling a different peptide to Compound 8 The non-covalent complexes of HLA-B27 with the cognate peptides (GRIDKPILK and GRAFVTIGK) melted at 72°C and 60°C, respectively.
The data indicate that covalently bound peptides with an aziridine replacing arginine stabilize HLA molecules approximately like non-covalently bound peptides, in one case stabilizing slightly more and in one less. Although the stability to thermal denaturation is comparable for non-covalent and covalent complexes, the covalently bound peptides should resist dissociating at 37°C for much longer than the non-covalently bound peptides . Covalent MHC-peptide complexes like those reported here may find use generating anergy if administered alone (see, Kozono, H. , White, J., Clements, J. , Marrack, P. & Kappler, J. (1994) Nature 369, 151-154) or activation if administered with co-ligands for inducing costimulatory signals as suggested by Schwartz, R.H. (1992) Cell 71, 1065-1068. A non-peptide ligand capable of crossing cellular membranes to block selectively HLA-B27, based on the same aziridine specificity can also be prepared.
OTHER EMBODIMENTS
From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
For example, the strategy can be used to form covalent complexes of peptides or other ligands with HLA- B27 does not add any new amino acids to the surface of the MHC molecule (that might be immunogenic) , but instead forms the covalent attachment deep in a pocket buried by the bound peptide. In addition, the aziridine strategy can be generalized to other proteins (i.e., recombinant class I MHC molecules) by mutating residues in the binding region (i.e., the P2 pocket residues) to those in
HLA-B27. The reverse experiment, engineering an HLA-A2 P2 specificity pocket into HLA-B27 by mutating residues 9, 24, 45, 66, 67, and 70 has been reported by Colbert, R. A., Rowland-Jones, S. L., McMichael, A. J. & Frelinger, J. A. (1993) Proc . Natl . Acad. Sci . USA 90, 6879-6883, resulting in the desired effect of altering the specificity for the P2 position of bound peptide but retaining the same ability to interact with T cells as the unmodified protein. The reverse can be similarly accomplished, HLA-B27 P2 pocket residues can be incorporated into HLA-A2. The success of the Colbert et al . experiment further suggests that any small adjustments in the local shape of the MHC molecule that might accompany covalent bond formation will not affect T-cell recognition, since the covalent bond formation
(Figure 1) is a much smaller modification than six amino acid substitutions.
Also contemplated within the scope of this invention are peptide analogs obtained by back modification of the above-described MHC-blocking peptides, e.g., replacement of at least one of the peptide bonds with -CH2-NH-, CH2-S-, or the like. Similarly, alkyl groups can be readily substituted by alkenyl, alkynyl or alkyl ether groups. Thus, other embodiments are also within the claims.
What is claimed is:
Claims
CLAIMS A compound of the formula
wherein each of R1 and R2, independently, is hydroxy, halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, alkyl carboxylate, a Michael acceptor, amino, alkylamino, ammonium, or alkyl ammonium, or together Rx and R2 are 0, NH, NH2 +, or NZ, where Z is alkyl or aryl ; X is C to C6 alkyl, substituted aryl, or deleted; R3 is H, alkyl, or aryl;
R4 is alkyl, aryl, -NH-W, or -C(=0)-Y, where W is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group; and
Rs is H, alkyl, aryl, -NH-W', or -C(=0)-Y', where W' is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y' is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group, or an amino acid residue bonded at its amino group.
2. The compound of claim 1, wherein:
Rj, is halogen, alkyl sulfonate, carboxylate, or aryl sulfonate and R2 is hydroxy, amino, alkylamino, ammonium, or alkyl ammonium, or together R1 and R2 are 0, NH2\ or NH; and
X is a C2 to C4 alkyl.
3. The compound of claim 2, wherein: R3 is H;
R4 is -NH-W, where W is an amino acid residue bonded at its carbonyl group or a peptide moiety bonded at its terminal carbonyl group; and
R5 is a -C(=0)-Y', where Y' is a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group.
4. The compound of claim 3, wherein:
W is an amino acid residue bonded at its carbonyl group ; and
Y' is a peptide moiety bonded at its terminal amino group .
5. The compound of claim 4, wherein:
Rx is alkyl sulfonate and R2 is an ammonium, or together Rx and R2 are 0, or NH; X is C4 alkyl; and the amino acid residue is a glycine residue.
6. The compound of claim 4, wherein a portion of the peptide moiety is identical to a portion of a selected peptide.
7. The compound of claim 4, wherein a portion of the peptide moiety is identical to a portion of an antigenic peptide.
8. The compound of claim 7, wherein the peptide moiety contains between 2 and 10 amino acid residues.
9. A method of forming a ligand-protein complex comprising the steps of: providing a protein having an arginine-specific binding region, the binding region including a nucleophilic residue; and adding a ligand to bind with the protein at the arginine-specific binding region, the ligand having a moiety which reacts with the nucleophilic residue, whereby the moiety of the ligand and the nucleophilic residue of the protein form a covalent bond between the ligand and the protein.
10. The method of claim 9, wherein: the arginine-specific binding region includes a thiol, a thiol and a carboxyl, or two carboxyl groups; and the moiety is halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, carboxylate, a Michael acceptor, aziridine, or epoxide.
11. The method of claim 10, wherein the arginine- specific binding region includes a thiol and a carboxyl.
12. The method of claim 11, wherein the moiety is aziridine, or epoxide.
13. The method of claim 9, wherein the step of providing the protein includes the step of altering a binding region of the protein to introduce the arginine- specific binding region.
14. The method of claim 13, wherein: the arginine-specific binding region includes a thiol , a thiol and a carboxyl , or two carboxyl groups ; and the moiety is halogen, haloalkyl, haloalkyl carbonyl, alkyl sulfonate, aryl sulfonate, alkyl carboxylate, a Michael acceptor, aziridine, or epoxide.
15. The method of claim 14, wherein the arginine- specific binding region includes a thiol and a carboxyl.
16. The method of claim 15, wherein the moiety is aziridine, or epoxide.
17. A covalently linked ligand-protein complex comprising a protein having an arginine-specific binding region and a ligand covalently bonded to the binding region of the protein, said ligand having the formula
wherein one of Ri and R2 is hydroxy, alkyl, alkyl carbonyl, amino, alkyl amino, ammonium, or alkyl ammonium, and the other of Rx and R2 is the covalent bond to the protein;
X is C1 to C6 alkyl, substituted aryl, or deleted;
R3 is H, alkyl, or aryl; R4 is alkyl, aryl, -NH-W, or -C(=0)-Y, where W is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group; and
R5 is H, alkyl, aryl, -NH-W', or -C(=0)-Y', where W' is H, alkyl, aryl, an amino acid residue bonded at its carbonyl group, or a peptide moiety bonded at its terminal carbonyl group, and Y' is alkyl, alkoxy, amino, substituted amino, hydroxyl, a peptide moiety bonded at its terminal amino group, or an amino acid residue bonded at its amino group.
18. The complex of claim 17, wherein: the arginine-specific binding region includes a thiol , a thiol and carboxyl , or two carboxyl groups ;
Rt is the covalent bond between the ligand and the protein; R2 is hydroxy, alkyl, alkyl carbonyl, amino, alkyl amino, ammonium, or alkyl ammonium; R3 is H; and X is a C2 to C4 alkyl .
19. The complex of claim 17, wherein: the arginine-specific binding region includes a thiol, a thiol and carboxyl, or two carboxyl groups;
Rx is hydroxy, alkyl, alkyl carbonyl, amino, alkyl amino, ammonium, or alkyl ammonium;
R2 is the covalent bond between the ligand and the protein;
R3 is H; and
X is a C2 to C4 alkyl.
20. The complex of claim 19, wherein:
R4 is -NH-W, where W is an amino acid residue bonded at its carbonyl group or a peptide moiety bonded at its terminal carbonyl group; and R5 is a -C(=0)-Y', where Y' is a peptide moiety bonded at its terminal amino group or an amino acid residue bonded at its amino group.
21. The complex of claim 20, wherein:
W is an amino acid residue bonded at its carbonyl group; and
Y' is a peptide moiety bonded at its terminal amino group.
22. The complex of claim 21, wherein: R-L is hydroxy, amino, or ammonium; X is C4 alkyl; and the amino acid residue is a glycine residue.
23. The complex of claim 22, wherein the arginine-specific binding region includes a thiol and carboxyl .
24. The complex of claim 21, wherein a portion of the peptide moiety is identical to a portion of a selected peptide.
25. The complex of claim 21, wherein a portion of the peptide moiety is identical to a portion of an antigenic peptide.
26. The complex of claim 25, wherein the peptide moiety contains between 2 and 10 amino acid residues.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2708196P | 1996-09-30 | 1996-09-30 | |
US60/027,081 | 1996-09-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998014208A1 WO1998014208A1 (en) | 1998-04-09 |
WO1998014208A9 true WO1998014208A9 (en) | 1998-09-11 |
Family
ID=21835579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/017483 WO1998014208A1 (en) | 1996-09-30 | 1997-09-30 | Reactive ligands and covalent ligand-protein complexes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1998014208A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
AP2007004161A0 (en) | 2005-04-28 | 2007-10-31 | Pfizer Ltd | Amino acid derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625986A (en) * | 1967-12-28 | 1971-12-07 | Nat Distillers Chem Corp | Bis 1, 1 isocyanatoalkyl cycloalkanes |
US5137929A (en) * | 1991-06-21 | 1992-08-11 | Allied-Signal Inc. | Additives which stabilize hydrohalocarbon blowing agent in polyurethane and polyisocyanurate foam formulations during polymerization |
-
1997
- 1997-09-30 WO PCT/US1997/017483 patent/WO1998014208A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ficht et al. | Solid‐phase synthesis of peptide and glycopeptide thioesters through side‐chain‐anchoring strategies | |
Hojo et al. | Development of a Linker with an Enhanced Stability for the Preparation of Peptide Thioesters and Its Application to the Synthesis of a Stable-Isotope-Labelled HU-Type DNA-Binding Protein. | |
PT832096E (en) | SYNTHESIS OF PROTEINS THROUGH NATIVE CHEMICAL LIGACATION | |
Sureshbabu et al. | Preparation, isolation, and characterization of N α-Fmoc-peptide isocyanates: Solution synthesis of oligo-α-peptidyl ureas | |
JP5789254B2 (en) | Lysine compounds and their use in site-selective and functional group-selective modification of peptides and proteins | |
WO2011098999A2 (en) | Chemical preparation of ubiquitin thioesters and modifications thereof | |
Weiss et al. | Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine. | |
Lumbierres et al. | Solid‐Phase Synthesis of Lipidated Peptides | |
EP3432935B1 (en) | Site-specific bio-conjugation methods and compositions useful for nanopore systems | |
Abboud et al. | A straightforward methodology to overcome solubility challenges for N-terminal cysteinyl peptide segments used in native chemical ligation | |
TW200831527A (en) | Method of peptide synthesis | |
Saporito et al. | The chemical synthesis of the GstI protein by NCL on a X‐Met site | |
KR20030046389A (en) | Nucleophile-stable thioester generating compounds, methods of production and use | |
WO1998014208A9 (en) | Reactive ligands and covalent ligand-protein complexes | |
WO1998014208A1 (en) | Reactive ligands and covalent ligand-protein complexes | |
US6787612B1 (en) | Resin derivatization method and uses thereof | |
Slaitas et al. | A Novel N‐(Pyrrolidinyl‐2‐methyl) glycine‐Based PNA with a Strong Preference for RNA over DNA | |
JP5730197B2 (en) | Method for producing peptide thioester | |
CN105622424A (en) | Compound and preparation method and application thereof | |
WO1992006107A1 (en) | Process for purifying synthetic peptide, and linker and linker-combining solid-phase carrier used in said process | |
CA2415478A1 (en) | Compounds targeted to cellular locations | |
US20050096456A1 (en) | Compounds comprising pseudo-amino acids | |
TWI549963B (en) | Ncl-adapted method for efficiently producing polypeptide fragments | |
Haney | Development of Dynamic, Bioorthogonal Peptide Cross-Linking Methods | |
Gross | Synthetic studies on bovine pancreatic trypsin inhibitor (BPTI). I. Optimized stepwise protocols. II. Segment condensation strategies |